Table 3.
Clinical characteristics of participants in the 3rd dose subgroups
| Characteristics | 3rd dose subgroups |
|
|---|---|---|
| Uninfected (n = 9) | COVID-19 infection (n = 10) | |
| Maternal vaccine-related characteristics | ||
| Third vaccine dose received, % (n) | ||
| BTN162b2 (Pfizer-BioNTech) | 44% (4) | 30% (3) |
| mRNA-1273 (Moderna) | 56% (5) | 70% (7) |
| Infant age at 3rd dose, months | ||
| Mean (SD) | 6.8 (3.7) | 4.7 (3.4) |
| Median (min, max) | 5.5 (0.8, 11.9) | 5.2 (−1.7a, 9.4) |
| Days between third dose and symptom assessment | ||
| Mean (SD) | 83 (92) | 121 (85) |
| Median (min, max) | 42 (15, 260) | 91.5 (29, 269) |
| SARS-CoV-2 infection characteristicsb | ||
| SARS-CoV-2 infections, % (n) | ||
| Mother and infant | 80% (8) | |
| Mother only | 20% (2) | |
| Neither mother nor infant | 100% (9) | |
| Infant age at time of maternal infection, months | ||
| Mean (SD) | 7.1 (3.5) | |
| Median (min, max) | 7.8 (−0.8a, 12.0) | |
| Days between maternal 3rd dose and infection | ||
| Mean (SD) | 72 (38) | |
| Median (min, max) | 72 (23, 141) | |
The 3rd dose subgroups did not differ significantly on any variable in this table (comparisons exclude the 3 participants included in both subgroups).
a
One infant had a negative age at both the maternal 3rd dose and maternal infection because both occurred during pregnancy, prior to the infant’s birth.
b
Of the 10 COVID-19 infections, 2 were diagnosed in late December 2021, 5 in January 2022, 2 in February 2022, and 1 in early March 2022.